Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| Regina | Rectal | Neoadjuvant | Regorafenib + nivolumab + short course RT in intermediate risk stage II-III |
| AZUR-2 | CRC | Neoadjuvant | Rand. study of perioperative Dostarlimab mono vs. SOC (surgery + adj chemo) in T4N0 or Stage III dMMR/MSI-H resectable CRC |
| IMCODE003 (GO44479) | Pancreas | Adjuvant | Autogen cevumeran IV + atezo + mFOLFIRINOX vs. mFOLFIRINOX; screening before surgery |
| Fortitude101 (20210096) | Gastric | 1L | Bemarituzumab vs. placebo + FOLFOX6 in FGFR2b positive disease (IHC) |
| Destiny04 | Gastric | 2L | Trastuzumab deruxtecan vs. paclitaxel-ramucirumab in HER2+ (IHC 3+/2+) disease |
| Fortitude102 (20210098) | Gastric | 1L | Bermarituzumab vss placebo + Nivolumab + mFOLFOX6 in FGFR2b positive disease (IHC) |
| Nalpac | Pancreas | 2L | Naliri vs Nalirinox. PD after 1st line gemcitabine mono or gem/abraxane |
| RGX202-002 | CRC | 2L | Ompenaclid vs. placebo + FOLFIRI+bevacizumab in RAS mutant CRC |
| Stereopac | Pancreas | Neoadjuvant | preop mFOLFIRINOX (or gem/NabP) +/- SBRT in borderline resectable |
| Mountaineer-03 (SGNTUC-029) | CRC | 1L | Tucatinib+trastuzumab + mFOLFOX6 vs. mFOLFOX6 +/- bevacizumab/cetuximab in HER2+, RAS wt CRC |
| Imbrave152 | HCC | 1L | Tiragolumab (anit-TIGIT) vs. placebo + atezolizumab + bevacizumab |
| REPLACE (TRIO 041) | HCC | 1L | Regorafenib + pembrolizumab vs. TACE or TARE |